Clinical Trial Update: the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines

View source ↗

Summary

This clinical trial update examines five-year antibody persistence after vaccination with IPV, MMR, and HepA-L vaccines. The study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis A
• Measles
• Mumps
• Poliomyelitis
• Rubella

Drugs mentioned

• HepA-L vaccine (Hepatitis A vaccine)
• IPV (Inactivated poliovirus vaccine)
• MMR vaccine (Measles, Mumps, and Rubella vaccine)

Snippet

Sponsor: China National Biotec Group Company Limited | Conditions: Polio, Measles | Status: NOT_YET_RECRUITING